Abstract:BackgroundTumorigenicity represents a critical challenge in stem cell-based therapies requiring rigorous monitoring. Conventional approaches for tumorigenicity evaluation are based on animal models and have numerous limitations. Brain organoids, which recapitulate the structural and functional complexity of the human brain, have been widely used in neuroscience research. However, the capacity of brain organoids for tumorigenicity evaluation needs to be further elucidated.MethodsA cerebral organoid model produced from human pluripotent stem cells (hPSCs) was employed. Meanwhile, to enhance the detection sensitivity for potential tumorigenic cells, we created a glioblastoma-like organoid (GBM organoid) model from TP53-/-/PTEN-/- hPSCs to provide a tumor microenvironment for injected cells. Midbrain dopamine (mDA) cells from human embryonic stem cells were utilized as a cell therapy product. mDA cells, hPSCs, mDA cells spiked with hPSCs, and immature mDA cells were then injected into the brain organoids and NOD SCID mice. The injected cells within the brain organoids were characterized, and compared with those injected in vivo to evaluate the capability of the brain organoids for tumorigenicity evaluation. Single-cell RNA sequencing was performed to identify the differential gene expression between the cerebral organoids and the GBM organoids.ResultsBoth cerebral organoids and GBM organoids supported maturation of the injected mDA cells. The hPSCs and immature mDA cells injected in the GBM organoids showed a significantly higher proliferative capacity than those injected in the cerebral organoids and in NOD SCID mice. Furthermore, the spiked hPSCs were detectable in both the cerebral organoids and the GBM organoids. Notably, the GBM organoids demonstrated a superior capacity to enhance proliferation and pluripotency of spiked hPSCs compared to the cerebral organoids and the mouse model. Kyoto Encyclopedia of Genes and Genomes analysis revealed upregulation of tumor-related metabolic pathways and cytokines in the GBM organoids, suggesting that these factors underlie the high detection sensitivity for tumorigenicity evaluation.ConclusionsOur findings suggest that brain organoids could represent a novel and effective platform for evaluating the tumorigenic risk in stem cell-based therapies. Notably, the GBM organoids offer a superior platform that could complement or potentially replace traditional animal-based models for tumorigenicity evaluation.

Establishment and Validation of Glioma Patient-Derived Organoid Models

Establishment of Patient-Derived Organoid Models of Lower-Grade Glioma.

The generation of glioma organoids and the comparison of two culture methods

Opportunities and challenges of glioma organoids

Organoids: Construction and Application in Gastric Cancer

Organoid Models of Glioblastoma: Advances, Applications and Challenges

GlioME: A Novel Organoid Model Retaining the Glioma Mi-croenvironment for Personalized Drug Screening and Thera-peutic Evaluation

Utility of the Cerebral Organoid Glioma 'GLICO' Model for Screening Applications

A novel integrated system using patient-derived glioma cerebral organoids and xenografts for disease modeling and drug screening

Glioblastoma organoid technology: an emerging preclinical models for drug discovery

Glioblastoma Organoids: Pre-Clinical Applications and Challenges in the Context of Immunotherapy

Generating Patient-Derived Gliomas within Cerebral Organoids

Modeling glioblastoma tumor progression via CRISPR-engineered brain organoids

A Tumorigenicity Evaluation Platform for Cell Therapies Based on Brain Organoids

Establishment of tumor microenvironment-preserving organoid model from patients with intracranial meningioma

Protocol for Generating in Vitro Glioma Models Using Human-Induced Pluripotent- or Embryonic-Stem-cell-derived Cerebral Organoids.

The Advancements of Organoids Push the Boundaries of Glioblastoma Research

Organoids: A Platform Ready for Glioblastoma Precision Medicine?

Generation and biobanking of patient-derived glioblastoma organoids and their application in CAR T cell testing

MODL-04. ESTABLISHMENT OF TUMOR MICROENVIRONMENT-PRESERVING ORGANOID MODEL FROM PATIENTS WITH INTRACRANIAL MENINGIOMA

Creation and Development of Patient-Derived Organoids for Therapeutic Screening in Solid Cancer